Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (Note: The metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on August 11, 2017. The report details the entry into material definitive agreements and amendments to existing credit facilities to support corporate activities, specifically the acquisition of EUROIMMUN Medizinische Labordiagnostika AG.
Key Financial Metrics and Debt Structure
- New Term Loan Facility: Established a 364-day unsecured term loan facility with a principal amount of $200 million.
- Interest Rates:
- Eurocurrency Loans: Adjusted LIBO Rate plus a margin of 1.00% to 1.75% based on debt ratings.
- ABR Loans: Alternate Base Rate plus a margin of 0.00% to 0.75% based on debt ratings.
- Fees: A ticking fee of 0.10% to 0.25% on commitments, accruing from October 1, 2017, until the Commitment Expiration Date.
- Revolving Credit Agreement Amendment: Amended to remove foreign currency sublimits and adjust financial covenants.
- Covenants: Includes a debt-to-capitalization ratio covenant (if investment grade), leverage ratio, and interest coverage ratio covenants under certain circumstances.
Material Changes Versus Prior Period
The filing represents a significant change in the company's capital structure and debt capacity:
- Debt Incurrence: The company secured new financing specifically to fund the EUROIMMUN Acquisition and general corporate purposes.
- Covenant Relaxation: The amendment to the Revolving Credit Agreement allows for a higher consolidated leverage ratio through the fiscal quarter ending July 1, 2018, and permits the assumption of existing indebtedness from acquired entities.
- Facility Terms: The removal of the foreign currency sublimit under the revolving facility provides greater flexibility in currency usage.
Guidance, Outlook, and Risks
Management Commentary and Purpose: The primary driver for these financial actions is the pending acquisition of a majority equity interest in EUROIMMUN Medizinische Labordiagnostika AG. The new term loan facility is designed to finance this transaction.
Risks and Contingencies:
- Commitment Expiration: The availability of the $200 million term loan is subject to a "Commitment Expiration Date," which is the earliest of December 31, 2017, the closing of the EUROIMMUN Acquisition, or the abandonment/termination of the acquisition agreement.
- Covenant Compliance: The company must adhere to customary affirmative and negative covenants, including limitations on liens, investments, and further indebtedness.
- Interest Rate Risk: Variable interest rates tied to LIBO and Alternate Base Rates expose the company to market rate fluctuations.
Key Facts for Investor Verification
- Verify the status of the EUROIMMUN Acquisition and whether the $200 million term loan was drawn down prior to the Commitment Expiration Date.
- Confirm the company's current debt rating to determine the specific interest rate margins and ticking fees applicable.
- Review subsequent filings to ensure compliance with the amended leverage ratio and interest coverage covenants through July 1, 2018.
- Check for any public announcements regarding the abandonment or termination of the Share Sale Agreement, which would trigger the expiration of the loan facility.